Korro Bio KRRO
NASDAQ KRRO
$12.94 +0.01 (+0.08%)
As of: Sep 10, 2026 · 2:59 PM EDT

Korro Bio (KRRO) Assets Average (2019 - 2026)

Korro Bio's (KRRO) quarterly Assets Average came in at $173.5 million in Q2 2026, down 9.29% on a YoY basis from $191.3 million in Q2 2025, and up 16.81% quarter-over-quarter from $148.6 million in Q1 2026.

Analysis

Korro Bio (KRRO) Assets Average (2019 - 2026) Analysis & Trends

Korro Bio (KRRO) has reported Assets Average for 8 consecutive years, with $173.5 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Assets Average fell 9.29% year-over-year to $173.5 million; the trailing twelve-month figure through Jun 2026 stood at $173.5 million (down 9.29% YoY), and the FY2025 full-year result was $169.9 million, down 24.15% from the prior year.
  • Assets Average grew to $173.5 million in Q2 2026 per KRRO's latest filing, from $148.6 million in the prior quarter.
  • Across five years, Assets Average topped out at $246.6 million in Q3 2024 and bottomed at $62.9 million in Q3 2023.
  • Historically, Assets Average has averaged $161.5 million across 5 years, with a median of $164.1 million in 2022.
  • The sharpest annual moves came in 2023 and 2024: Assets Average slumped 55.99% in 2023, then jumped 292.21% in 2024.
  • Over 5 years, Assets Average stood at $104.9 million in 2022, then rose by 27.77% to $134.0 million in 2023, then soared by 75.28% to $234.9 million in 2024, then slumped by 41.45% to $137.5 million in 2025, then rose by 26.18% to $173.5 million in 2026.
  • According to Business Quant data, Assets Average over the past three periods registered $173.5 million, $148.6 million, and $137.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Assets Avg. (Qtr)
1 Amgen 206.78 Bn 192.79 Bn 7.24 Bn 94.07 Bn
2 Gilead Sciences 179.92 Bn 176.74 Bn 6.22 Bn 52.82 Bn
3 Vertex Pharmaceuticals 131.39 Bn 123.54 Bn 2.84 Bn 26.95 Bn
4 Regeneron Pharmaceuticals 81.91 Bn 73.91 Bn 3.93 Bn 41.30 Bn
5 Argenx Se 60.35 Bn 55.17 Bn 1.37 Bn -
6 Moderna 53.67 Bn 48.54 Bn 52.00 Mn 11.22 Bn
7 Alnylam Pharmaceuticals 33.12 Bn 29.81 Bn 992.69 Mn 5.34 Bn
8 Biogen 31.92 Bn 30.63 Bn 1.96 Bn 30.78 Bn
9 Roivant Sciences 29.23 Bn 29.23 Bn 1.16 Mn 5.51 Bn
10 Korro Bio 227.98 Mn 112.95 Mn - 173.53 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 173.53 Mn
Mar 31, 2026 148.56 Mn
Dec 31, 2025 137.53 Mn
Sep 30, 2025 170.99 Mn
Jun 30, 2025 191.32 Mn
Mar 31, 2025 214.22 Mn
Dec 31, 2024 234.89 Mn
Sep 30, 2024 246.57 Mn
Jun 30, 2024 223.79 Mn
Mar 31, 2024 209.82 Mn
Dec 31, 2023 134.01 Mn
Sep 30, 2023 62.87 Mn
Jun 30, 2023 90.44 Mn
Mar 31, 2023 87.62 Mn
Dec 31, 2022 104.88 Mn
Sep 30, 2022 142.84 Mn
Jun 30, 2022 157.30 Mn
Mar 31, 2022 175.15 Mn
Dec 31, 2021 193.77 Mn
Sep 30, 2021 211.20 Mn